We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Erlotinib in Pancreatic Cancer: A Major Breakthrough?
- Authors
Ko, Andrew H.
- Abstract
The article focuses on the issue of erlotinib for use in combination with gemcitabine to patients with advanced pancreatic cancer. The U.S. Food and Drug Administration approved the combination which provides a small positive step in the right direction on such diseases. According to the author, the approval provides important proof of ideas regarding the use of newer "targeted" therapies in pancreatic cancer. Other combination regimens have demonstrated some benefits including survival.
- Subjects
UNITED States; CANCER chemotherapy; COMBINATION drug therapy; PANCREATIC cancer; CANCER patients; UNITED States. Food &; Drug Administration; DRUG approval
- Publication
Oncology (08909091), 2007, Vol 21, Issue 14, p1706
- ISSN
0890-9091
- Publication type
Article